Cohance Lifesciences Ltd (COHANCE) Stock Analysis: Valuation, Latest Results, Financial Ratios & DeciZen Rating

BSE: 543064 | NSE: COHANCE | Pharmaceuticals & Drugs | Small Cap

Cohance Lifesciences Share Price

542.15 -6.95 -1.27%
as on 05-Dec'25 15:26

Cohance Lifesciences Ltd (COHANCE) Stock Analysis: Valuation, Latest Results, Financial Ratios & DeciZen Rating

BSE: 543064 | NSE: COHANCE | Pharmaceuticals & Drugs | Small Cap

DeciZen - make an informed investing decision on Cohance Lifesciences

Based on:

Overall Rating
Login to view analysis. Bole Toh

1. Quality


Login to view analysis.

2. Valuation


Login to view analysis.

3. Price Trend


Login to view analysis.

Cohance Lifesciences stock performance -

Key Ratios
mw4me loader
P/E Ratio (CD):
84.76
Market Cap:
21,006.8 Cr.
52-wk low:
540.5
52-wk high:
1,337.9

Is Cohance Lifesciences Ltd an attractive stock to invest in?


Login to view analysis.

10 Year X-Ray of Cohance Lifesciences: Login to view analysis.

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Cohance Lifesciences Ltd has performed well in majority of the past ten years indicating its past ten year financial track record is very good

Value Creation

Value Creation Index Colour Code Guide

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
ROCE % 0%0%0%23.9%50.2%40.8%45.9%33.4%21.2%18.4%-
Value Creation
Index
NANANA1.13.52.02.41.50.60.6-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 0003788341,0101,3201,3401,0511,1981,814
Sales YoY Gr.-NANANA120.7%21.1%30.8%1.5%-21.6%13.9%-
Adj EPS 00001213.915.315.110.310.26.5
YoY Gr.-NANANANA15.9%10.5%-1.2%-31.7%-1.3%-
BVPS (₹) 000033.246.46068.280.56699
Adj Net
Profit
000111305353390385263260248
Cash Flow from Ops. 00050.4407383330457358288-
Debt/CF from Ops. 0001.60.50.40.30.20.10.3-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales NA7.5%-3.2%13.9%
Adj EPS NA-3.2%-12.7%-1.3%
BVPSNA14.7%3.2%-18%
Share Price - 7.1% 5.5% -58.1%

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
Return on
Equity %
00018.842.534.928.823.613.913.97.9
Op. Profit
Mgn %
00046.146.243.944.142.838.631.323.4
Net Profit
Mgn %
00029.436.63529.628.82521.413.7
Debt to
Equity
0000.10.20.10.1000.10
Working Cap
Days
0000196175172195213160121
Cash Conv.
Cycle
0000815769891049575

Recent Performance Summary

Login to view analysis.
Login to view analysis.

Latest Financials - Cohance Lifesciences Ltd.

Standalone Consolidated
TTM EPS (₹) 7.3 6.5
TTM Sales (₹ Cr.) 1,587 1,814
BVPS (₹.) 115.3 99
Reserves (₹ Cr.) 4,371 3,749
P/BV 4.76 5.55
PE 75.69 84.76
From the Market
52 Week Low / High (₹) 540.50 / 1337.85
All Time Low / High (₹) 87.05 / 1359.00
Market Cap (₹ Cr.) 21,007
Equity (₹ Cr.) 38.3
Face Value (₹) 1
Industry PE 40.7

Management X-Ray of Cohance Lifesciences:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Valuation of Cohance Lifesciences - Consolidated Basis

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

mw4me loader

Event Update

Login/Register to view analysis.

Analyst's Notes

data not found
No data found!

Key Ratios of Cohance Lifesciences

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Sales3788341,0101,3201,3401,0511,198
Operating Expenses 206449567739766646822
Manufacturing Costs53122150189184137150
Material Costs101225298394403312301
Employee Cost 306576100118135250
Other Costs 223643556162122
Operating Profit 172385443582574406375
Operating Profit Margin (%) 45.4%46.1%43.9%44.1%42.8%38.6%31.3%
Other Income 1181492466259
Interest 32312913712
Depreciation 11243239485577
Exceptional Items 0000000
Profit Before Tax 158405468668560406344
Tax 498810521414810579
Profit After Tax 109317362454411300265
PAT Margin (%) 28.9%38.0%35.9%34.4%30.7%28.6%22.1%
Adjusted EPS (₹)0.012.514.217.816.211.810.5
Dividend Payout Ratio (%)0%20%14%28%37%0%0%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25

Equity and Liabilities

Shareholders Fund 5788451,1811,5271,7352,0491,680
Share Capital 0132525252525
Reserves 5788321,1551,5021,7102,0231,654
Minority Interest000000144
Debt8318514196693976
Long Term Debt0913628506
Short Term Debt839410667653970
Trade Payables547183106704280
Others Liabilities 1021911712382361241,051
Total Liabilities 8161,2921,5761,9672,1102,2543,031

Fixed Assets

Gross Block3474575706948769292,046
Accumulated Depreciation77100128160212260332
Net Fixed Assets 2713574415346636701,713
CWIP 1111029630165179256
Investments 7338542598536904337
Inventories157175201283313231167
Trade Receivables148117102236111134284
Cash Equivalents 13141047685189
Others Assets 10919018423725486186
Total Assets 8161,2921,5761,9672,1102,2543,031

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Cash Flow From Operating Activity 50407383330457385288
PBT 158405468668560406344
Adjustment 14353641371760
Changes in Working Capital -8854-12-194672-32
Tax Paid -33-86-109-184-146-110-83
Cash Flow From Investing Activity -65-413-311-136-195-362-255
Capex -57-103-111-75-286-52-156
Net Investments -7-325-201-30084-310623
Others -215-02396-0-723
Cash Flow From Financing Activity 267-76-156-242-403
Net Proceeds from Shares 0000000
Net Proceeds from Borrowing 5291-55-10-24-5-2
Interest Paid -3-17-9-6-12-7-10
Dividend Paid -19-64-25-102-20400
Others -4-313-39-3-2816
Net Cash Flow 111-53720-1836

Finance Ratio

PARTICULARSMar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Ratios
ROE (%)18.9244.5835.7833.5225.2115.8714.2
ROCE (%)23.8750.2140.7645.9233.4121.2218.44
Asset Turnover Ratio0.460.790.70.750.660.480.45
PAT to CFO Conversion(x)0.461.281.060.731.111.281.09
Working Capital Days
Receivable Days142584047474264
Inventory Days152736867819461
Payable Days1931019487806674

Cohance Lifesciences Ltd Stock News

Cohance Lifesciences Ltd FAQs

The current trading price of Cohance Lifesciences on 05-Dec-2025 15:26 is ₹542.1.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 04-Dec-2025 the market cap of Cohance Lifesciences stood at ₹21,006.8.
The latest P/E ratio of Cohance Lifesciences as of 04-Dec-2025 is 75.69.
The latest P/B ratio of Cohance Lifesciences as of 04-Dec-2025 is 4.76.
The 52-week high of Cohance Lifesciences is ₹1,337.9 and the 52-week low is ₹540.5.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Cohance Lifesciences is ₹1,587 ( Cr.) .

About Cohance Lifesciences Ltd

Suven Pharmaceuticals Limited, a company incorporated in November 2018, has become Wholly Owned Subsidiary of Suven Life Sciences Limited, effective February 2019. Suven Life Sciences Limited, post the Board meeting on February 5, 2019, announced demerger of Suven Life Sciences Limited into: Suven Life Sciences Limited, the demerged entity, to continue innovative research focused on Central Nervous System (CNS) disorders to meet huge unmet global medical needs. Suven Pharmaceuticals Limited, the resultant entity, to continue the CRAMS business operations. The Scheme of Arrangement has since been approved by the National Company Law Tribunal (NCT), Hyderabad bench vide its order on 6th January 2020.

Pursuant to the Scheme of Arrangement between Suven Life Sciences Limited (‘Demerged Company’), Suven Pharmaceuticals Limited (‘Resulting Company’) and their respective shareholders and creditors, duly approved by the National Company Law Tribunal (NCLT), Hyderabad Bench, vide its Order dated 06th January, 2020, the Demerged Undertaking (as defined in the Scheme) of the Demerged Company has been demerged from Suven Life Sciences Limited and the same has been transferred to and vested in Suven Pharmaceuticals Limited with effect from 1st October, 2018, being the Appointed Date fixed in the said Scheme of Arrangement.

The Scheme, has become operative from the Appointed Date i.e., 1st October, 2018, but has become effective on 9th January, 2020 being the date on which certified copies of the Order of the NCLT, Hyderabad Bench sanctioning the Scheme was filed with the Registrar of Companies, Hyderabad, Telangana, both by the Demerged Company and Resulting Company.

Business area of the company

The company is a bio-pharmaceutical company, incorporated with the object of being engaged in the business of development and manufacturing of New Chemical Entity (NCE) based Intermediates, Active Pharmaceutical Ingredients (API), Speciality Chemicals and formulated drugs under contract research and manufacturing services for global pharmaceutical, biotechnology and chemical companies. Suven Pharma Inc., a Delaware Company, is a WOS (wholly owned subsidiary) of SPL, is a SPV (Special Purpose Vehicle) created on 9th March 2019, for undertaking various business opportunities in Pharma Industry.

Business segments

  • Pharmaceutical Solutions
  • Active Pharma ingredients
  • Intermediates
  • Formulations
To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×